Systemic and mucosal immune responses to sublingual or intramuscular Human Papilloma Virus antigens in healthy female volunteers

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Huo, Zhiming ^a   Bissett, Sara L ^b   Giemza, Raphaela ^a   Beddows, Simon ^b   Oeser, Clarissa ^a   Lewis, David J M ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; CAPSID PROTEIN; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 11; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6; ONCOPROTEIN; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SECRETING CELL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MUCOSAL IMMUNITY; PAPILLOMAVIRUS INFECTION; REPRODUCIBILITY; SECRETORY CELL; TRANSLATIONAL RESEARCH; UTERINE CERVIX MUCUS; VAGINA; VAGINA SECRETION; VOLUNTEER; WART VIRUS; ALPHAPAPILLOMAVIRUS; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; UTERINE CERVIX;

HUMAN PAPILLOMAVIRUS;

ADMINISTRATION, SUBLINGUAL; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CERVIX UTERI; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; VAGINA; YOUNG ADULT;

EID: 84858395364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033736     Document Type: Article

References (27)

1. Czerkinsky C, Cuburu N, Kweon MN, Anjuere F, Holmgren J, (2011) Sublingual vaccination. Hum Vaccin 7: 110-114.
2. Cho HJ, Kim JY, Lee Y, Kim JM, Kim YB, et al. (2010) Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 28: 2598-2606.
3. Cuburu N, Kweon MN, Hervouet C, Cha HR, Pang YY, et al. (2009) Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 183: 7851-7859.
4. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, et al. (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25: 8598-8610.
5. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, et al. (2010) Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28: 5582-5590.
6. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, et al. (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 105: 1644-1649.
7. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4: e6999.
8. Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, et al. (2005) Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97: 181-188.
9. Frati F, Moingeon P, Marcucci F, Puccinelli P, Sensi L, et al. (2007) Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 28: 35-39.
10. Czerkinsky C, Holmgren J, (2010) Mucosal Delivery Routes for Optimal Immunization: Targeting Immunity to the Right Tissues. Curr Top Microbiol Immunol.
11. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, et al. (2011) Phase I Randomised Clinical Trial of an HIV-1(CN54), Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. PLoS One 6: e25165.
12. Mills KH, Cosgrove C, McNeela EA, Sexton A, Giemza R, et al. (2003) Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 71: 726-732.
13. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.
14. Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, et al. (2011) Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29: 8585-8590.
15. Ferguson M, Wilkinson DE, Heath A, Matejtschuk P, (2011) The first international standard for antibodies to HPV 16. Vaccine 29: 6520-6526.
16. Lewis DJ, Novotny P, Dougan G, Griffin GE, (1991) The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B subunit. Eur J Immunol 21: 2087-2094.
17. Desai S, Chapman R, Jit M, Nichols T, Borrow R, et al. (2011) Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis 38: 622-629.
18. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, et al. (2007) Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer 97: 989-991.
19. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
20. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2: 868-878.
21. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
22. Schiller JT, Lowy DR, (2010) Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 64: 23-41.
23. Frazer I, (2007) Correlating immunity with protection for HPV infection. International Journal of Infectious Diseases 11: S10-S16.
24. Moingeon P, Lombardi V, Saint-Lu N, Tourdot S, Bodo V, et al. (2011) Adjuvants and vector systems for allergy vaccines. Immunol Allergy Clin North Am 31: 407-419 xii.
25. Pomfret TC, Gagnon JM Jr, Gilchrist AT, (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 36: 1-9.
26. Clemens JD, Jertborn M, Sack D, Stanton B, Holmgren J, et al. (1986) Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine. J Infect Dis 154: 175-178.
27. Levine MM, Hughes TP, Young CR, O'Donnell S, Craig JP, et al. (1978) Antigenicity of purified glutaraldehyde-treated cholera toxoid administered orally. Infect Immun 21: 158-162.